Onkológia 1/2020

Analysis of accessibility of medicines from the perspective of IHP of MOH

Slovakia has the sixth highest treatable mortality rate, indicating that health interventions are not available in a timely and effective manner. We cannot accurately determine how many of the 8,000 treatable deaths could have been averted if modern cancer treatments were available. Today, we have only about a third of the medicines that have been EMA approved since 2011. The availability of cancer medicines will continue to be a problematic issue in the future, as the Slovak economy is slowing down and the Ministry of Finance is putting pressure on savings through Value for Money project. Based on an approximated horizontal screening, we expect new oncology and hematology medicines worth up to EUR 1 billion per year in the coming years. It is therefore essential to start with the process of changing the pharmaco-economy, harmonizing health and social care and gradually increasing the budget.

Keywords: accessibility, horizontal-screening, treatable mortality